What this is
- How it works
- How it works isn't classified yet
- Tested for
- Infertility (IVF Patients)
- Main trialPhase 3
- “The goal of this multicenter, randomized, placebo-controlled, double-blind clinical trial is toto evaluate the efficacy and safety of a human menopausal gonadotropin (hMG) in the development of multiple follicles, pregnancy, and cumulative live birth as part of an Assisted Reproductive Technology (ART) cycle in in women with a diagnosis of infertility.”In the company’s words, NCT07216742 on ClinicalTrials.gov
Other drugs for Infertility (IVF Patients)
- FertiloGameto, Inc. · Phase 3
- Follitropin alfa/lutropin alfaMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Phase 3
- PKB171Prokrea BCN, S.L. · Phase 2/3
- MibavademabRegeneron · Phase 2
- Teverelix DPAntev Ltd. · Phase 2
- QL1012DQilu Pharmaceutical · Phase 1
Coming up1
- Nov 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Nov 2028 | Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026